Company Overview and News


Add THR
to your dashboard

Headline News

Novartis AG Returns Global Eye Drug Rights to ThromboGenics NV

2017-09-18 biospace
Leuven, Belgium, 18th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced today that it will regain full global rights to JETREA® from Alcon, a Novartis company, based on a mutual agreement that the unique characteristics of JETREA make Thrombogenics a better fit for building a sustainable long-term niche business. (21-0)

Diabetic Macular Edema Pipeline Therapeutics Companies and Drugs Profile Insights 2017 Available at RnR Market Research

2017-07-24 prnewswire
Diabetic Macular Edema Pipeline Therapeutics Drugs Market Insights 2017 provides in depth insights on the pipeline drugs and their development activities around the Diabetic Macular Edema. The report covers the product profiles development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. (0-2)

ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement

2017-07-10 prnewswire
ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB ("BioInvent") (OMXS: BINV) today announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The revisions to the existing agreement have been aligned with each company's strategic ambitions and therapeutic focus.

ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain

2017-06-08 prnewswire
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will give a presentation at the European Society of Ophthalmology Congress, which is held from June 10-13 in Barcelona, Spain.

ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

2017-05-24 prnewswire
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will give a presentation at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting, which is being held in Budapest, Hungary from May 25-27.

ThromboGenics Business Update - Q1 2017

2017-05-11 prnewswire
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, today issues a business update for the three months period ending 31 March 2017.

New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

2017-05-02 prnewswire
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that its research and development team, associated experts and others will be presenting 12 papers and posters including new ophthalmic research findings at the upcoming ARVO (Association for Research in Vision and Ophthalmology) 2017 Annual Meeting which is being held from May 7th - 11th, 2017 in Baltimore, US.

ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

2017-04-20 prnewswire
ThromboGenics, a biotechnology company focusing on novel treatments for back of the eye disease and diabetic eye disease, announced it has achieved an important milestone in the advancing of the pre-clinical development of its THR-149, a novel plasma kallikrein inhibitor, which the company is developing for the treatment of Diabetic Macular Edema (DME). Following today's announcement, ThromboGenics will now start pivotal tox studies which are a last step before starting the clinical development which is expected for early 2018.

ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma

2017-01-17 prnewswire
ONCURIOUS NV, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, today announces that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma. Today's decision by the EC follows the earlier positive opinion issued by the European Medicine Agency (EMA).

ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)

2017-01-10 prnewswire
THR-317 could become an attractive alternative or add-on treatment for current anti-VEGF medicines when treating DME or DR  

ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)

2016-08-08 prnewswire
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye diseases, today announces that the results from its 2 Year OASIS Phase IIIb study with JETREA® (ocriplasmin) have been published in the renowned AAO Journal Ophthalmology.

Watts Water (WTS) Hits a 52-Week High: Right Time to Buy?

2016-06-21 zacks
Shares of Watts Water Technologies, Inc. (WTS - Analyst Report) scaled a 52-week high of $60.58 on Jun 20. The new high came on the back of expected benefits from European transformation program, acquisitions and growth in operational efficiencies. The stock closed a notch lower at $59.82 at the close of trading yesterday, with a solid one-year return of over 9.4% and year-to-date return of 20.4%. The average volume of shares traded over the last three months was roughly 113K.

ThromboGenics Business Update - Q1 2016

2016-05-13 prnewswire
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for diabetic eye disease, today issues a business update for the three month period ending 31 March, 2016.

New Ocriplasmin Research Findings Presented

2016-04-27 prnewswire
New Data Confirm Appropriate Patient Selection Leads to Improved Treatment Outcomes, With no new Safety Signals Observed 

ThromboGenics focuses on drug development in 2015

2016-03-17 northern-observer
Biopharmaceutical company ThromboGenics reported revenue declined in 2015 to €11.2 million from €13.8 million in 2014 but net losses for the year were substantially reduced.